Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Korean Red Ginseng appears to adverse events in adults taking 24 weeks Placebo and comparative assessment. And exploratory as Korean Red Ginseng blood sugar control, reduce body fat, URTI prevention, cardiovascular risk, renal function, cholesterol, improve, fatigue, and determine the impact on biological age.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Korean Red Ginseng | Experimental | Patients receive oral Korean Red Ginseng twice daily for 24 weeks. Treatment repeats every 4, 12, 24 weeks for 3 courses |
|
| Placebo | Placebo Comparator | Patients receive oral placebo twice daily for 24 weeks. Treatment repeats every 4, 12,24 weeks for 3 courses |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Korean Red Ginseng | Dietary Supplement |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| All adverse events occurring up to 24 weeks time after taking the Investigational product | up to 24 weeks time after taking the Investigational product |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse events that occurred up to 24 weeks to collect all focus point after taking the Investigational product | up to 24 weeks to collect all focus point after taking the Investigational product | |
| Cardiovascular adverse events that occurred after taking the Investigational product |
| Measure | Description | Time Frame |
|---|---|---|
| glucose, insulin, HbA1c levels, HOMA-IR index variation | up to 24 weeks time after taking the Investigational product | |
| BMI, waist circumference variation | up to 24 weeks time after taking the Investigational product |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kyungsoo Kim, M.D., Ph.D | The Catholic University of Korea | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Catholic Universtiy of Korea. Seoul St Mary's Hospital | Seoul | 137-701 | South Korea |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D006973 | Hypertension |
| D006949 | Hyperlipidemias |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000713447 | Asian ginseng |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| up to 24 weeks time after taking the Investigational product |
| Gastrointestinal adverse events that occurred after ingestion of Investigational product | up to 24 weeks time after taking the Investigational product |
| Neuropsychiatric adverse events that occurred after ingestion of Investigational product | up to 24 weeks time after taking the Investigational product |
| Grade 3 adverse events that occurred after ingestion of Investigational product | up to 24 weeks time after taking the Investigational product |
| Baseline by 24 weeks after the change in quality of life measures ingestion of Investigational product | up to 24 weeks time after taking the Investigational product |
| adiponectin, leptin levels of variation | up to 24 weeks time after taking the Investigational product |
| URTI (Upper respiratory tract infection) rates | up to 24 weeks time after taking the Investigational product |
| hs-CRP, IL-6, homocysteine concentration of variation | up to 24 weeks time after taking the Investigational product |
| eGFR, change amount of urine protein | up to 24 weeks time after taking the Investigational product |
| Variation of CFS (Chalder fatigue scale) | up to 24 weeks time after taking the Investigational product |
| variation of biological age | up to 24 weeks time after taking the Investigational product |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |